Salivary evaporative natural compounds in obese patientswith gingivitis and periodontitis using Gas chromatography- Massspectrometry machine

Not Applicable

• Conditions: Health Condition 1: K053- Chronic periodontitis

• Registration Number: CTRI/2023/08/056369
• Lead Sponsor: Dr Sakshi Kundu

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 August 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Group A â?? Obese periodontally healthy

1. The BMI >= 30kg /m2

2. No clinical attachment loss

3. Age between 30 to 50 years

4. Bleeding on probing <= 10%

5. Patient willing to participate in the study.

Group B -Obese Gingivitis subjects

1. The BMI >= 30kg /m2

2. Bleeding on probing >= 10%

3. Age between 30 to 50 years

4. Patient willing to participate in the study.

Obese periodontitis subjects

1. The BMI >= 30kg /m2

2. Generalized periodontitis

3. Age between 30 to 50 years

4. Patient willing to participate in the study

Exclusion Criteria

1. Periodontal therapy last 3 months.

2. Antibiotics in the last 3 months.

3. Patients on NSAID therapy.

4. Pregnant and lactating females.

5. Subjects using any form of tobacco.

6. History of nasal obstructions and mouth breathers

7. History of known systemic diseases

8. History of use of mouthwashes

9. Subjects using any kind of Dental pro

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
There is no difference in the levels of Volatile organic compounds(1-Tetradecanol & 1-Hexadecanol) in obese with <br/ ><br>gingivitis, periodontitis, & periodontally healthy subjects using Gas Chromatography-Mass <br/ ><br>Spectrometry.Timepoint: At the first visit (Baseline), one month

Secondary Outcome Measures

Name	Time	Method
1.To estimate salivary VOC levels (1-Tetradecanol & 1-Hexadecanol ) & clinical <br/ ><br>parameters in obese subjects with periodontitis using GC-MS. <br/ ><br>2.To estimate salivary VOC levels (1-Tetradecanol and 1-Hexadecanol ) and clinical <br/ ><br>parameters in obese subjects with gingivitis using GC-MS. <br/ ><br>3.To estimate salivary VOC levels (1-Tetradecanol and 1-Hexadecanol ) and clinical <br/ ><br>parameters in periodontally healthy obese subjects using GC-MS. <br/ ><br>4.To compare the salivary VOC levels (1-Tetradecanol and 1-Hexadecanol ) and clinical <br/ ><br>parameters in obese subjects using GC-MS.Timepoint: At the first visit (baseline) one month